A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04063163 |
Recruitment Status : Unknown
Verified March 2022 by Shanghai Henlius Biotech.
Recruitment status was: Active, not recruiting
First Posted : August 21, 2019
Last Update Posted : September 30, 2022
|
Sponsor:
Shanghai Henlius Biotech
Information provided by (Responsible Party):
Shanghai Henlius Biotech
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Unknown |
---|---|
Actual Primary Completion Date : | October 22, 2021 |
Estimated Study Completion Date : | December 2022 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):